Adial Pharmaceuticals Inc
| NASDAQ: ADIL | Healthcare / Biotechnology / USA |
| 2.13 | +0.0800 | +3.90% | Vol 15.83K | 1Y Perf -68.34% |
| Nov 29th, 2023 16:00 DELAYED |
| BID | 2.00 | ASK | 2.25 | ||
| Open | 2.07 | Previous Close | 2.05 | ||
| Pre-Market | - | After-Market | 2.50 | ||
| - - | 0.37 17.37% |
| Target Price | 8.50 | Analyst Rating | Moderate Buy 1.67 | |
| Potential % | 299.06 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/43 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-77 | Income Ranking | — - | |
| Price Range Ratio 52W % | 2.35 | Earnings Rating | Strong Buy | |
| Market Cap | 2.59M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.33 | |
| Beta | 1.08 |
Today's Price Range 2.052.25 | 52W Range 1.8215.00 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -0.47% | ||
| 1 Month | 9.23% | ||
| 3 Months | -41.32% | ||
| 6 Months | -69.13% | ||
| 1 Year | -68.34% | ||
| 3 Years | -96.34% | ||
| 5 Years | -97.78% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -239.10 | |||
ROE last 12 Months | -248.96 | |||
ROA (5Y Avg) | -68.90 | |||
ROA last 12 Months | -172.59 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -239.94 | |||
Return on invested Capital Q | -45.03 | |||
Return on invested Capital Y | -103.86 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.50 | ||||
| 1.74 | ||||
| - | ||||
| - | ||||
| -1.00 | ||||
| -0.50 | ||||
| 2.00 | ||||
| 0.20 | ||||
| 3.87M | ||||
| Forward PE | -1.45 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.30 | ||||
| 5.10 | ||||
| 0.03 | ||||
| 0.04 | ||||
| -40.90 | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -1.50 | -1.33 | 11.33 |
| Q01 2023 | -3.50 | -2.75 | 21.43 |
| Q04 2022 | -3.75 | -2.75 | 26.67 |
| Q03 2022 | -4.50 | -3.00 | 33.33 |
| Q02 2022 | -4.00 | -4.00 | 0.00 |
| Q01 2022 | -4.25 | -3.25 | 23.53 |
| Q03 2021 | -0.22 | -0.22 | 0.00 |
| Q02 2020 | - | -0.16 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -1.00 | 11.50 | Positive |
| 12/2023 FY | -4.93 | 10.36 | Positive |
| 3/2024 QR | -0.37 | 92.72 | Positive |
| 12/2024 FY | -1.46 | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -1.13 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 15.83K |
| Shares Outstanding | 1.22K |
| Shares Float | 959.77K |
| Trades Count | 213 |
| Dollar Volume | 34.11K |
| Avg. Volume | 21.92K |
| Avg. Weekly Volume | 8.70K |
| Avg. Monthly Volume | 11.92K |
| Avg. Quarterly Volume | 45.15K |
Adial Pharmaceuticals Inc (NASDAQ: ADIL) stock closed at 2.13 per share at the end of the most recent trading day (a 3.9% change compared to the prior day closing price) with a volume of 15.83K shares and market capitalization of 2.59M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 16 people. Adial Pharmaceuticals Inc CEO is Cary J. Claiborne.
The one-year performance of Adial Pharmaceuticals Inc stock is -68.34%, while year-to-date (YTD) performance is -60.37%. ADIL stock has a five-year performance of -97.78%. Its 52-week range is between 1.82 and 15, which gives ADIL stock a 52-week price range ratio of 2.35%
Adial Pharmaceuticals Inc currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 1.74, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -172.59%, a ROC of -239.94% and a ROE of -248.96%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Adial Pharmaceuticals Inc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-1.13 for the next earnings report. Adial Pharmaceuticals Inc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Adial Pharmaceuticals Inc is Moderate Buy (1.67), with a target price of $8.5, which is +299.06% compared to the current price. The earnings rating for Adial Pharmaceuticals Inc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Adial Pharmaceuticals Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Adial Pharmaceuticals Inc has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.58, ATR14 : 0.21, CCI20 : 18.54, Chaikin Money Flow : 0.14, MACD : -0.09, Money Flow Index : 58.41, ROC : 7.04, RSI : 45.89, STOCH (14,3) : 42.39, STOCH RSI : 0.88, UO : 38.72, Williams %R : -57.61), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Adial Pharmaceuticals Inc in the last 12-months were:
Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.
CEO: Cary J. Claiborne
Telephone: +1 434 422-9800
Address: 1180 Seminole Trail,Suite 495, Charlottesville 22901, VA, US
Number of employees: 16
